Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure

 
• By Amanda Micklus and Maureen Riordan

Plus news on recent financial activity by Mersana Therapeutics, Hyperion Therapeutics, Atterocor and Exelixis.

More from Archive

More from Pink Sheet